BMI’s patented cardio-vascular emulating CaVESWave® system has proven itself to be a versatile ex vivo and pharmacodynamic research platform, empowering vital research.
We provide customized ex vivo protocols to meet the specific aims of your study.
Tailored solutions allow an array of organs and tissue types to be perfused, including Kidney, Liver, Lungs, Intestine, Brains, and Vascularized Composite Allografts (VCA).
Temperature control ramping available from 4 to 37 degrees
The ability to recover discarded organs
Extend the time from 6 hours to more than 24 hours that the organs are viable for transplant
Proven and patented technology and ‘methods & apparatus’ regularly used to perfuse an array of different organs and tissue types
Customizable waveform on a portal and arterial circuit
Our edge to cloud data will give valuable information to the surgeons and patient
Provides detailed, real-time organ performance and viability data previously unavailable.
Customizable waveform on a portal and arterial circuit
Proven and patented technology and ‘methods & apparatus’ regularly used to perfuse an array of different organs and tissue types
Temperature control ramping available from 4 to 37 degrees
BMI OrganBankTM has developed its technology and capabilities in North Carolina’s world renowned research triangle, by serving and collaborating with leading institutions like Duke University’s ex vivo organ laboratory “DEVOL”, Wake Medical’s “WFIRM”, and UNC Chapel Hill’s Kidney Center.
Our patented technology has been deployed to support leading clinicians, researchers and organ specialists to perfuse and preserve an array of organs, and tissue, including animal and human kidney, lung, liver, small intestine, and vascularized composite allografts (VCAs) to allow vital therapies and clinical methodologies to be advanced.
BMI OrganBank’s laboratory platform, known as CaVESWave®, has CardioVascular Emulation technology at its core and is currently serving Duke, Yale University’s Neuroscience Lab, WFIRM, Porter Adventist, Colorado, with a number of new deployments in the mobilization.
CaVESWave® was considered the appropriate platform on which to perfuse human lungs to allow vital gene therapy to be advanced into debilitating disease impacting the respiratory system.
Similarly the platform has allowed research into the effects on vascular flow ex vivo of a new drug therapy on NonAlcoholic Steatohepatitis (NASH).
To further demonstrate its versatility, the CaVESWave® platform is assisting studies on behalf of the Department of Defense into the opportunity to undertake lower intestine transplants and vascularized composite allografts that could transform the lives of our horrifically injured servicemen and women and their families, not least leading to an effective Battlefield Recovery System™ (“BRS”).
BMI’s home laboratory in the First Flight Venture Center™ of the North Carolina Research Triangle Park will soon host research projects for clients in the BioPharma arena and our vision is to see this capability expanded to other geographies to serve our clients growing need.
During the COVID-19 pandemic era it has become evident that BioPharma professionals must find ways to expedite research programs in a way that allows them to fail early and succeed more quickly and cost-effectively.
© 2023 BMI OrganBank. All rights reserved by BMI LLC
